#Teechallaclothing Winter glamour wove its way through this week’s best beauty Instagrams. For Tracee Ellis Ross, that manifested as a heavy-handed wing of onyx liner, while Lizzo relied on a bombshell blowout and a hazy, romantic eye. Elle Fanning paused for a post-awards-show, pre-after-party selfie centering mussed peek-a-boo blonde and a red lip, as elsewhere, Justin Bieber proved a pouty visage and beanie go a long way, and Billie Eilish wore bangs and rust-rimmed lids. Finally, Selma Blair showcased her time in New York City, running around town with a tousled blonde pixie and generally radiating joy. Reveling in the Nebraska Huskers Youth 2023 shirt But I will love this human experience: the best beauty note of all. Are you excited?” Ellen Marmur, MD, asks me, beaming from behind her mask, when I settle into a treatment room at her white-walled Upper East Side office on a cold winter afternoon. The Manhattan-based dermatologist has just returned from a weekend at Revance’s headquarters in Nashville, where the pharmaceutical company hosted about 80 cosmetic dermatologists and plastic surgeons for a series of intensive seminars on Daxxify, the latest neuromodulator to receive FDA approval for the treatment of the glabella, the frequently furrowed lines between the eyebrows. In the company’s clinical trials, “Daxi,” as Marmur refers to it, had shown median outcomes lasting six months—sometimes up to nine months—more than twice as long as any other botulinum product on the market. As a member of Daxxify’s scientific advisory board since 2018, Marmur was one of the first providers to receive the injectable, which is being marketed as “the future of aesthetics” since it began its slow rollout at the end of last year. Her enthusiasm is palpable. “We’ve seen so many things come and go,” Marmur continues, prepping a syringe. “But really this broke through the noise.”
#Teechallaclothing There has been a lot of noise in the Nebraska Huskers Youth 2023 shirt But I will love this injectables space over the last 30 years. “Following Viagra, Botox is the second most recognizable pharmaceutical name in the world,” says Michael Kane, MD, a Manhattan-based plastic surgeon and self-proclaimed “injectables guy.” (After pilfering a vial of the original botulinum toxin from an ophthalmology colleague at Manhattan Eye, Ear, and Throat Hospital in 1991, Kane became the world’s largest provider of Botox from 1991 to 2002.) Now there’s also Dysport, and Xeomin, and the Seoul-born Jeuveau—all of which are designed to do the same thing: block the nerves that tell certain facial muscles to move, relaxing fine lines and wrinkles, among other benefits. Kane has consulted on all of them, and he’s been providing feedback on Daxxify—which was originally designed to transdermally deliver botulinum to the crow’s-feet through the skin, without a needle—for 17 years. “Every formulation has its own little personality,” Kane says, explaining that while each one uses different carrier and stabilizing proteins, any performance variation (faster or wider dispersion, for example) is mostly based on anecdotal evidence. “A lot of it is patient choice,” Kane concedes. “There’s a certain allure to newness, so if a patient is really happy with the new thing, I see no reason to switch them.” The flip side is also true: The “new thing” has a less-proven track record, which can steer patients toward the older formulas they know and trust. Daxxify’s defining personality just happens to be longevity, suggests Kane, the possible result of a proprietary peptide that cleaves the cell membrane and drags the large, positively charged peptide through the cell, then through the next cell, before it latches onto the negatively charged nerve terminal. According to gossip in derm circles, the FDA required Revance to test its molecule as an injectable for safety purposes, which is when they discovered that its clinical outcomes outlasted the competition, what Marmur calls its “disruptive moment.”
Comments